Literature DB >> 20091615

Neuraxial anaesthesia for lower-limb revascularization.

Fabiano T Barbosa1, Jairo C Cavalcante, Mário J Jucá, Aldemar A Castro.   

Abstract

BACKGROUND: Lower-limb revascularization surgery is used to reduce pain and sometimes to improve lower-limb function. The type of anaesthesia used during lower-limb revascularization may affect the risks of both good and bad outcomes.
OBJECTIVES: To determine the rates of death and major complications with spinal and epidural anaesthesia compared with other types of anaesthesia for lower-limb revascularization. SEARCH STRATEGY: We searched CENTRAL (The Cochrane Library 2008, Issue 2); MEDLINE (1960 to 10th June 2008); EMBASE (1982 to 10th June 2008); LILACS (1982 to 10th June 2008); CINAHL (1982 to 10th June 2008) and ISI Web of Science (1900 to 10th June 2008). SELECTION CRITERIA: We included randomized controlled trials that evaluated the effect of anaesthetic type in adults aged 18 years or older undergoing lower-limb revascularization surgery. DATA COLLECTION AND ANALYSIS: Two authors independently performed the data extraction. Primary outcomes were mortality, cerebral stroke, myocardial infarction, nerve dysfunction and postoperative lower-limb amputation rate. The secondary outcome analysed was pneumonia. We judged risk of bias with four criteria: randomization and allocation concealment methods, blinding of treatment and outcome assessment and completeness of follow up. To assess heterogeneity we used the I(2) statistic. We summarized dichotomous data as odds ratio (OR) with 95% confidence interval (CI) using a random-effects model. MAIN
RESULTS: We included four studies that compared neuraxial anaesthesia with general anaesthesia. The total number of participants was 696, of whom 417 were allocated to neuraxial anaesthesia and 279 to general anaesthesia. Participants allocated to neuraxial anaesthesia had a mean age of 67 years and 59% were men. Participants allocated to general anaesthesia had a mean age of 67 years and 66% were men. There was no difference between participants allocated to neuraxial or general anaesthesia in: mortality rate (OR 0.89, 95% CI 0.38 to 2.07; 696 participants, four trials); myocardial infarction (OR 1.23, 95% CI 0.56 to 2.70; 696 participants, four trials); and lower-limb amputation rate (OR 0.84, 95% CI 0.38 to 1.84; 465 participants, three trials). Pneumonia was less common following neuraxial anaesthesia than general anaesthesia (OR 0.37, 95% CI 0.15 to 0.89; 201 participants, two trials). AUTHORS'
CONCLUSIONS: There was insufficient evidence available from the included trials that compared neuraxial anaesthesia with general anaesthesia to rule out clinically important differences for most clinical outcomes. Neuraxial anaesthesia may reduce pneumonia. No conclusions can be drawn with regard to mortality, myocardial infarction and rate of lower-limb amputation or less common outcomes.

Entities:  

Mesh:

Year:  2010        PMID: 20091615     DOI: 10.1002/14651858.CD007083.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  4 in total

Review 1.  Preoperative cardiac risk assessment for noncardiac surgery in patients with heart failure.

Authors:  Jenica Upshaw; Michael S Kiernan
Journal:  Curr Heart Fail Rep       Date:  2013-06

Review 2.  Neuraxial blockade for the prevention of postoperative mortality and major morbidity: an overview of Cochrane systematic reviews.

Authors:  Joanne Guay; Peter Choi; Santhanam Suresh; Natalie Albert; Sandra Kopp; Nathan Leon Pace
Journal:  Cochrane Database Syst Rev       Date:  2014-01-25

3.  Influences of the aging process on acute perioperative pain management in elderly and cognitively impaired patients.

Authors:  Thomas Halaszynski
Journal:  Ochsner J       Date:  2013

4.  Comparative study of two anesthesia methods according to postoperative complications and one month mortality rate in the candidates of hip surgery.

Authors:  Saied Morteza Heidari; Hasanali Soltani; Saied Jalal Hashemi; Reihanak Talakoub; Bahram Soleimani
Journal:  J Res Med Sci       Date:  2011-03       Impact factor: 1.852

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.